Millennium Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Millennium Management’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-50	Closed	-$190K	–	4078
2014 Q2	$190K	Buy	+50	New	+$188K	﹤0.01%	3144

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Millennium Management's NBSE Position: Q4 2022 in Review

Millennium Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2022, closing a stake of 1,115 shares — an estimated $9K sold.

Millennium Management first reported a position in NBSE in Q1 2014 and held it in 19 quarters. The position peaked at $12.2M in Q1 2014. 34 funds tracked by Wall St. Rank hold NBSE as of Q4 2022.

Millennium Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Millennium Management sold 1,115 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $9K.
Millennium Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2014 and held it in 19 quarters.
Millennium Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $12.2M in Q1 2014.
34 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Millennium Management's 13F filing for Q4 2022, filed 14 Feb 2023.